Modality
ASO
MOA
PD-L1i
Target
EGFR
Pathway
Fibrosis
Fabry
Development Pipeline
Preclinical
~Jun 2015
→ ~Sep 2016
Phase 1
~Dec 2016
→ ~Mar 2018
Phase 2
Jun 2018
→ Aug 2030
Phase 2Current
NCT03380931
2,932 pts·Fabry
2018-06→2030-08·Recruiting
NCT07528427
506 pts·Fabry
2023-12→2028-09·Completed
3,438 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2028-09-102.4y awayPh3 Readout· Fabry
2030-08-094.4y awayPh3 Readout· Fabry
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P2/3
Recruit…
P2/3
Complet…
Catalysts
Ph3 Readout
2028-09-10 · 2.4y away
Fabry
Ph3 Readout
2030-08-09 · 4.4y away
Fabry
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03380931 | Phase 2/3 | Fabry | Recruiting | 2932 | PFS |
| NCT07528427 | Phase 2/3 | Fabry | Completed | 506 | MRD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| AZN-6870 | AstraZeneca | Phase 2/3 | EGFR | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| TAK-1836 | Takeda | Preclinical | EGFR | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| Motainavolisib | Amgen | NDA/BLA | CD47 | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA | |
| Miriglumide | Alnylam | Phase 3 | CD3 | |
| Zanurapivir | Neurocrine | NDA/BLA | EGFR |